Patents by Inventor Norio Katayama

Norio Katayama has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10232026
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Grant
    Filed: December 13, 2016
    Date of Patent: March 19, 2019
    Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Publication number: 20170165343
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Application
    Filed: December 13, 2016
    Publication date: June 15, 2017
    Applicants: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Patent number: 9539209
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Grant
    Filed: June 4, 2010
    Date of Patent: January 10, 2017
    Assignees: NATIONAL INSTITUTE OF INFECTIOUS DISEASES, M BIO TECHNOLOGY INC.
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Publication number: 20120135067
    Abstract: Disclosed is a vaccine which has a high therapeutic effect on mycoplasma infection and is highly safe. For the purpose of developing effective therapeutic methods for mycoplasma infection, mycoplasma-mimic particles which are effective as a vaccine for mycoplasma infection are provided, and also provided are bacterium-mimic particles including common bacteria. Bacterium-mimic particles such as mycoplasma-mimic particles can be provided by producing liposome particles in which a lipid antigen specific to a pathogenic bacterium such as mycoplasma is contained as a liposome-constituting lipid component. The administration of the mycoplasma-mimic particles enables the induction of a potent immunological activity in living bodies. The mycoplasma-mimic particles can be used as an excellent vaccine for the prevention or treatment of mycoplasma infection.
    Type: Application
    Filed: June 4, 2010
    Publication date: May 31, 2012
    Applicants: M BIO TECHNOLOGY INC., NATIONAL INSTITUTE OF INFECTIOUS DISEASES
    Inventors: Kazuhiro Matsuda, Koji Ichiyama, Sachie Matsuda, Yuko Sasaki, Yoshichika Arakawa, Ryo Harasawa, Yoshihiro Nishida, Norio Katayama, Yasuo Endo, Nobuo Nomura
  • Patent number: 6456182
    Abstract: In a common mode choke coil, a closed magnetic circuit core (2) is divided in parallel with its magnetic circuit, and formed by superimposing together for integration a first divided magnetic core (2a), a second divided magnetic core (2b) and a third divided magnetic core (2c) which are made of an oxide magnetic substance having the high permeability. Since the closed magnetic circuit core (2) is made of the oxide magnetic substance having the high permeability, the impedance in the low frequency band (10 kHz side) is large. Also, since the sectional area of the closed magnetic circuit core (2) (divided magnetic core) is set to be small, the permeability in the high frequency band (10 MHz side) becomes high due to the dimensional resonance phenomenon, and then the impedance also becomes large. For that reason, the noise in the wide frequency band of 10 kHz to 10 MHz can sufficiently be attenuated.
    Type: Grant
    Filed: March 3, 2000
    Date of Patent: September 24, 2002
    Assignee: Minebea Co., Ltd.
    Inventors: Norio Katayama, Toshinori Okamoto